Mattea Reinisch

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 533 citations

Breast Oncology, Her2-low-positive Breast Cancer, Individual Patient Data +9

A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients

Sherko Küemmel, Joerg Heil, Anna Rueland et al. · Annals of Surgery · 2020 · 163 citations

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Hope S. Rugo, Joyce O’Shaughnessy, F Boyle et al. · Annals of Oncology · 2022 · 109 citations · Full text

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

D.W. Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2020 · 97 citations

Breast Oncology, Oncology, Lba15 Primary Results +8